Literature DB >> 18843768

Alemtuzumab (Campath-1H) for treatment of refractory polymyositis.

Ben Thompson, Paul Corris, James A L Miller, Robert G Cooper, John P Halsey, John D Isaacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18843768

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

Review 1.  Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors:  Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal:  Expert Rev Clin Immunol       Date:  2015-08-27       Impact factor: 4.473

Review 2.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

3.  Immunotherapy of inflammatory myopathies: practical approach and future prospects.

Authors:  Marinos C Dalakas
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 4.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

Review 5.  Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review.

Authors:  Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 6.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 7.  Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 8.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 9.  Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.

Authors:  Ilaria Pagnini; Antonio Vitale; Carlo Selmi; Rolando Cimaz; Luca Cantarini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 10.817

10.  Long-term efficacy of alemtuzumab in polymyositis.

Authors:  Tobias Ruck; Stefan Bittner; Tanja Kuhlmann; Heinz Wiendl; Sven G Meuth
Journal:  Rheumatology (Oxford)       Date:  2014-12-30       Impact factor: 7.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.